NDAORALTABLET, EXTENDED RELEASE
Approved
Jan 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
MINIPRESS XL (prazosin hydrochloride) by Pfizer is clinical pharmacology the exact mechanism of the hypotensive action of prazosin is unknown. First approved in 1992.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MINIPRESS XL is an extended-release oral tablet formulation of prazosin hydrochloride, an alpha-1 adrenergic receptor antagonist approved in 1992. It lowers blood pressure by blocking postsynaptic alpha-adrenoceptors, reducing total peripheral resistance without causing reflex tachycardia. Prazosin is indicated for hypertension management with a favorable hemodynamic profile that preserves cardiac output and renal function.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30%), signaling smaller brand teams focused on maintenance and lifecycle optimization rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY The exact mechanism of the hypotensive action of prazosin is unknown. Prazosin causes a decrease in total peripheral resistance and was originally thought to have a direct relaxant action on vascular smooth muscle. Recent animal studies, however, have suggested that the…
Indications
Worked on MINIPRESS XL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.